To the Editor:Chronic thromboembolic pulmonary hypertension(CTEPH)is a rare but serious condition characterized by obstruction of the pulmonary arteries due to thromboembolic events and subsequent vascular remodeling,...To the Editor:Chronic thromboembolic pulmonary hypertension(CTEPH)is a rare but serious condition characterized by obstruction of the pulmonary arteries due to thromboembolic events and subsequent vascular remodeling,which leads to pulmonary hypertension(PH).Classified as Group 4 in the 2022 PH guidelines by the European Society of Cardiology and the European Respiratory Society,CTEPH poses significant risks,including progressive PH,right ventricular dysfunction,and mortality if left untreated.Despite established diagnostic and treatment guidelines,the exact national prevalence of CTEPH remains largely unknown due to the absence of organized registries,with estimates ranging from 3 to 30 cases per million people.Although CTEPH is commonly thought to follow acute pulmonary embolism(PE),epidemiological data reveal a discrepancy;studies suggest that only 0.1%to 3.8%of PE patients may develop CTEPH.展开更多
基金supported by the National Key Research and Development Program of China(No.2023YFC2507200)Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences(CIFMS)(No.2021-I2M-1-049)+1 种基金National High Level Hospital Clinical Research Funding(No.2022-NHLHCRF-LX-01-0203)National Natural Science Foundation of China(Nos.82241029,and 81970058).
文摘To the Editor:Chronic thromboembolic pulmonary hypertension(CTEPH)is a rare but serious condition characterized by obstruction of the pulmonary arteries due to thromboembolic events and subsequent vascular remodeling,which leads to pulmonary hypertension(PH).Classified as Group 4 in the 2022 PH guidelines by the European Society of Cardiology and the European Respiratory Society,CTEPH poses significant risks,including progressive PH,right ventricular dysfunction,and mortality if left untreated.Despite established diagnostic and treatment guidelines,the exact national prevalence of CTEPH remains largely unknown due to the absence of organized registries,with estimates ranging from 3 to 30 cases per million people.Although CTEPH is commonly thought to follow acute pulmonary embolism(PE),epidemiological data reveal a discrepancy;studies suggest that only 0.1%to 3.8%of PE patients may develop CTEPH.
